Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3WKO5)

Drug Name
AG490 Drug Info
Synonyms
(E)-N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 133550-30-8; AG-490; Tyrphostin B42; Tyrphostin AG 490; AG 490; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; Tyrphostin AG490; tyrphostin AG-490; AG-490 (Tyrphostin B42); alpha-Cyano-(3,4-dihydroxy)-N-benzylcinnamide; N-Benzyl-2-cyano-3-(3,4-dihydroxyphenyl)acrylamide; 134036-52-5; (2E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; CHEMBL56543; (E)-N-benzyl-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; (2E)-2-CYANO-3-(3,4-DIHYDROXYPHENYL)-N-(PHENYLMETHYL)-2-PROPENAMIDE; SMR001230665
Cross-matching ID
PubChem CID
5328779
ChEBI ID
CHEMBL56543
CAS Number
CAS 133550-30-8
TTD Drug ID
D0GZ7B

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Ovarian steroidogenesis 2.29 0.00e+0 41/51 (80.39%) AKR1C3;HSD17B7;INSR;...
Glycerolipid metabolism 2.03 5.54e-3 44/61 (72.13%) AKR1B10;AKR1B1;PLPP3;...
Protein processing in endoplasmic reticulum 2.00 7.38e-3 127/171 (74.27%) HERPUD1;HSPA5;DERL2;...
Folate biosynthesis 1.91 8.31e-3 23/26 (88.46%) AKR1C3;AKR1B10;AKR1B1;...
Amino sugar and nucleotide sugar metabolism 1.83 2.66e-2 38/48 (79.17%) UGDH;GPI;CYB5R2;...
Longevity regulating pathway 1.82 2.21e-2 90/151 (59.6%) INSR;IRS2;CREB3L1;...
Prostate cancer 1.78 4.11e-2 93/97 (95.88%) PLAT;PDGFRA;PDGFD;...
Primary bile acid biosynthesis -1.72 4.81e-2 15/17 (88.24%) HSD17B4;SCP2;ACOT8;...
Tight junction -1.82 1.87e-2 130/169 (76.92%) PRKAA1;MAP3K1;ROCK1;...
African trypanosomiasis -1.84 1.27e-2 32/37 (86.49%) IL18;IL1B;KNG1;...
Systemic lupus erythematosus -1.92 8.49e-3 45/135 (33.33%) ELANE;HLA-DQA1;HLA-DRB1;...
Asthma -1.93 1.27e-2 25/31 (80.65%) RNASE3;IL4;HLA-DOA;...
Complement and coagulation cascades -1.95 1.70e-2 76/85 (89.41%) F5;C8A;SERPINF2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM - 15uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.37uM - 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H